细胞重编程可通过调控细胞命运，诱导获得适用于临床治疗的目标细胞类型，开辟了再生医学新的路径。2006年，日本科学家山中伸弥（Shinya Yamanaka）借助病毒载体将Oct4、Sox2、Klf4和c-Myc四个转录因子（OSKM，即“山中因子”）导入成体细胞，将其重编程为诱导多能干细胞（iPS细胞），是生命科学研究里程碑式的突破。

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...

近日，贵州师范大学团队在国际顶级学术期刊《Cell》在线发表研究论文“Reprogramming of microspore fate via BBM-BAR1 for highly efficient in vivo ...

A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The discovery demonstrates a ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

One promising strategy to remuscularize the injured heart is the direct cardiac reprogramming of heart fibroblast cells into cardiomyocytes. Researchers have identified TBX20 as the key missing ...

The capacity of an organism to regenerate depends on cell dedifferentiation followed by proliferation. Mammals, in general, have limited regenerative capacity. Now, a team of researchers at the Salk ...

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...